The involvement of p62 in the development of liver tumors has been established, and it has been found that increased levels of p62 in non-tumor liver tissue can serve as a reliable biomarker for predicting the recurrence of HCC following therapeutic ablation, as demonstrated in both human and mouse models [44] (Table 1 and Table 2). The gene discussed is SQSTM1; the disease is neoplasm.